1,060
Participants
Start Date
September 30, 2010
Primary Completion Date
August 31, 2012
Study Completion Date
June 30, 2016
Gefitinib
250mg tablet oral, once daily until objective disease progression is documented or until other discontinuation criterion is met
Research Site, Plovdiv
Research Site, Sofia
Research Site, Stara Zagora
Research Site, Varna
Research Site, Vratsa
Research Site, Angers
Research Site, Saint-Herblain
Research Site, Athens
Research Site, Heraklion
Research Site, Larissa
Research Site, Thessaloniki
Research Site, Budapest
Research Site, Deszk
Research Site, Edelény
Research Site, Győr
Research Site, Mosdós
Research Site, Székesfehérvár
Research Site, Ancona
Research Site, Carpi
Research Site, Livorno
Research Site, Perugia
Research Site, Oslo
Research Site, Stavanger
Research Site, Trondheim
Research Site, Gdansk
Research Site, Krakow
Research Site, Lubin
Research Site, Olsztyn
Research Site, Otwock
Research Site, Szczecin
Research Site, Torun
Research Site, Warsaw
Research Site, Wroclaw
Research Site, Coimbra
Research Site, Lisbon
Research Site, Porto
Research Site, Vila Nova de Gaia
Research Site, Brasov
Research Site, Bucharest
Research Site, Cluj-Napoca
Research Site, Constanța
Research Site, Lleida
Research Site, Lugo
Research Site, Madrid
Research Site, Majadahonda
Research Site, Málaga
Research Site, Basel
Research Site, Chur
Research Site, Rapperswil-Jona
Research Site, Sursee
Research Site, Ankara
Research Site, Istanbul
Research Site, Izmir
Research Site, Aberdeen
Research Site, Birmingham
Research Site, Burnley
Research Site, Cambridge
Research Site, Dundee
Research Site, Liverpool
Research Site, Nottingham
Research Site, Wolverhampton
Lead Sponsor
AstraZeneca
INDUSTRY